Natera (NASDAQ:NTRA) CEO Sells $909,570.60 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,580 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total value of $909,570.60. Following the completion of the transaction, the chief executive officer owned 102,973 shares in the company, valued at $26,162,350.11. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, July 27th, Steven Leonard Chapman sold 2,190 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $570,473.10.
• On Thursday, June 4th, Steven Leonard Chapman sold 41,124 shares of Natera stock. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72.
• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $185,956.32.

Natera Stock Up 0.6%

Shares of NTRA stock traded up $1.60 during trading on Wednesday, hitting $253.82. The company had a trading volume of 925,147 shares, compared to its average volume of 1,091,572. The stock’s 50-day moving average is $244.16 and its two-hundred day moving average is $221.65. The stock has a market capitalization of $36.35 billion, a price-to-earnings ratio of -155.72 and a beta of 1.51. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in shares of Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. Wellington Management Group LLP boosted its position in Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. State Street Corp grew its holdings in shares of Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after acquiring an additional 72,087 shares during the period. Coatue Management LLC raised its position in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after acquiring an additional 2,463,008 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Natera by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock valued at $596,078,000 after purchasing an additional 11,689 shares during the period. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of research analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Natera in a report on Wednesday, July 15th. Wolfe Research started coverage on Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target on the stock. The Goldman Sachs Group started coverage on Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 price target for the company. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Natera in a research report on Monday, July 6th. Finally, Royal Bank Of Canada started coverage on shares of Natera in a research report on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.